Cargando…

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma

SIMPLE SUMMARY: This study investigated the relationship between erlotinib resistance and stemness in lung adenocarcinoma. NCAPG2 was identified as an erlotinib resistance gene and maintained the stemness of lung adenocarcinoma. ABSTRACT: Erlotinib is a highly specific and reversible epidermal growt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Shiyao, Huang, Jingjing, He, Hua, Liu, Yueying, Liang, Lu, Sun, Xiaoyan, Li, Yi, Cong, Li, Qing, Bei, Jiang, Yiqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497119/ https://www.ncbi.nlm.nih.gov/pubmed/36139554 http://dx.doi.org/10.3390/cancers14184395

Ejemplares similares

KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma
por: He, Hua, et al.
Publicado: (2022)

TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma
por: Liang, Lu, et al.
Publicado: (2022)

Novel Circulating Tumour Cell-Related Risk Model Indicates Prognosis and Immune Infiltration in Lung Adenocarcinoma
por: Liang, Lu, et al.
Publicado: (2022)

NCAPG stimulates lung adenocarcinoma cell stemness through aerobic glycolysis
por: Zhang, Zuwang, et al.
Publicado: (2023)

NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway
por: Wu, Yun, et al.
Publicado: (2021)

Analysis of PANoptosis-Related LncRNA-miRNA-mRNA Network Reveals LncRNA SNHG7 Involved in Chemo-Resistance in Colon Adenocarcinoma
por: Huang, Jingjing, et al.
Publicado: (2022)

Characterizing the Crosstalk of NCAPG with Tumor Microenvironment and Tumor Stemness in Stomach Adenocarcinoma
por: Xiang, Zheng, et al.
Publicado: (2022)

NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma
por: Zhan, Ping, et al.
Publicado: (2016)

NCAPG as a Novel Prognostic Biomarker in Glioma
por: Jiang, Xiulin, et al.
Publicado: (2022)

Pan-cancer analysis of the immune aspects and prognostic value of NCAPG2
por: Feng, Huidong, et al.
Publicado: (2023)

NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma
por: Zheng, Guangrong, et al.
Publicado: (2022)

PLAG1 and NCAPG‐LCORL in livestock
por: Takasuga, Akiko
Publicado: (2016)

The roles of GTPase-activating proteins in regulated cell death and tumor immunity
por: He, Hua, et al.
Publicado: (2021)

Increased expression of NCAPG (Non-SMC condensing I complex subunit G) is associated with progression and poor prognosis of lung adenocarcinoma
por: Wang, Xiaodong, et al.
Publicado: (2022)

NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma
por: Ren, Wenjun, et al.
Publicado: (2022)

NCAPG promotes the proliferation of hepatocellular carcinoma through the CKII-dependent regulation of PTEN
por: Zhang, Rongguiyi, et al.
Publicado: (2022)

NCAPG Promotes the Proliferation of Renal Clear Cell Carcinoma via Mediating with CDK1
por: Li, Huibing, et al.
Publicado: (2022)

NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression
por: Sun, Huanhuan, et al.
Publicado: (2022)

AC099850.3/NCAPG Axis Predicts Poor Prognosis and is Associated with Resistance to EGFR Tyrosine-Kinase Inhibitors in Lung Adenocarcinoma
por: Bao, Jiaqi, et al.
Publicado: (2022)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
por: Topcu, Atakan, et al.
Publicado: (2022)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

NCAPG Induces Cell Proliferation in Cardia Adenocarcinoma via PI3K/AKT Signaling Pathway
por: Zhang, Xinxin, et al.
Publicado: (2020)

Correction: NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression
por: Sun, Huanhuan, et al.
Publicado: (2022)

NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling
por: Gong, Chengwu, et al.
Publicado: (2019)

NCAPG is differentially expressed during longissimus muscle development and is associated with growth traits in Chinese Qinchuan beef cattle
por: Liu, Yu, et al.
Publicado: (2015)

Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines
por: Wang, Hui-Li, et al.
Publicado: (2019)

The U2AF65/circNCAPG/RREB1 feedback loop promotes malignant phenotypes of glioma stem cells through activating the TGF-β pathway
por: Li, Hao, et al.
Publicado: (2023)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma
por: Kurishima, Koichi, et al.
Publicado: (2014)

NCAPG Is a Promising Therapeutic Target Across Different Tumor Types
por: Xiao, Cuicui, et al.
Publicado: (2020)

Aberrant Expression of NCAPG is Associated with Prognosis and Progression of Gastric Cancer
por: Sun, Ding-Ping, et al.
Publicado: (2020)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
por: Dong, Jiang-Kai, et al.
Publicado: (2021)

NCAPG Dynamically Coordinates the Myogenesis of Fetal Bovine Tissue by Adjusting Chromatin Accessibility
por: Hu, Xin, et al.
Publicado: (2020)

Circular RNA circ0001955 promotes cervical cancer tumorigenesis and metastasis via the miR-188-3p/NCAPG2 axis
por: Wang, Wei, et al.
Publicado: (2023)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
por: Gonçalves, Ivone, et al.
Publicado: (2013)

Elevated mRNA Expression Levels of NCAPG are Associated with Poor Prognosis in Ovarian Cancer
por: Xu, Tao, et al.
Publicado: (2020)

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2014)

MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q50gfql376kkpqrln6erit342q